eCite Digital Repository

New-age adjuvants: friend or foe?


Petrovsky, N and Heinzel, S and Honda, Y and Lyons, AB, New-age adjuvants: friend or foe?, Biopharm International-The Applied Technologies of Biopharmaceutical Development, 20, (8) pp. A24-A33. ISSN 1542-166X (2007) [Refereed Article]


Older vaccines made from live or killed whole organisms were effective, but suffered from high reactogenicity. As vaccine manufacturers developed safer, less reactogenic subunit vaccines, they found that with lower reactogenicity came reduced vaccine effectiveness. Somewhat ironically, the solution proposed to boost immunogenicity in modern vaccines is to add back immune-activating substances such as toll-like receptor agonists - the very same contaminants removed from old-style vaccines. This raises the question of whether the vaccine field is moving forward or backward. We propose that by avoiding adjuvants that work through toll-like receptor (TLR) pathways, and instead focusing on adjuvants stimulating B-and T-cell immunity directly, one can minimize inflammatory cytokine production and consequent reactogenicity. We present data on a polysaccharide-based adjuvant candidate, Advax, that enhances immunogenicity without reactogenicity, suggesting that potent and well-tolerated vaccines for both adult and pediatric use are indeed possible.

Item Details

Item Type:Refereed Article
Research Division:Biomedical and Clinical Sciences
Research Group:Immunology
Research Field:Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Lyons, AB (Associate Professor Bruce Lyons)
ID Code:73626
Year Published:2007
Web of Science® Times Cited:8
Deposited By:Medicine
Deposited On:2011-10-19
Last Modified:2016-12-14

Repository Staff Only: item control page